Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a clinical-stage biotech like Centessa Pharmaceuticals can feel like navigating a maze of scientific jargon and risk factors. Pipeline updates on orexin agonists, the LockBody immuno-oncology platform, and critical cash-runway disclosures are scattered across hundreds of pages. Missing one footnote could mean overlooking a trial halt or royalty obligation.
Stock Titan’s AI decodes every Centessa Pharmaceuticals quarterly earnings report 10-Q filing and annual report 10-K simplified, surfacing what matters—R&D spend by program, milestone payments, and liquidity outlook. Need to see Centessa Pharmaceuticals insider trading Form 4 transactions? You’ll also get Centessa Pharmaceuticals Form 4 insider transactions real-time as they post, while side-by-side comparisons help you understand Centessa Pharmaceuticals SEC filings explained simply. Even sudden announcements, like the 8-K material events explained when SerpinPC was discontinued, land on your dashboard seconds after they hit EDGAR.
Investors use these insights to:
- Monitor Centessa Pharmaceuticals executive stock transactions Form 4 before key data read-outs
- Track progress of ORX750 and LB101 across filings without sifting through appendices
- Compare quarter-over-quarter spending using understanding Centessa Pharmaceuticals SEC documents with AI
- Review the proxy statement executive compensation details in plain English
Whether you’re preparing a valuation model or answering, “How do I read Centessa Pharmaceuticals earnings report filing analysis?”, Stock Titan delivers the context. Real-time updates, AI-powered summaries, and historical documents ensure you never miss a disclosure again.
Centessa Pharmaceuticals plc entered into an amended and restated sales agreement with Leerink Partners that allows it to issue and sell, from time to time, up to $250 million of American Depositary Shares in at-the-market offerings under an existing shelf registration statement. Leerink will act as sales agent and receive a commission of up to 3.0% of the gross proceeds from each sale, and the company will reimburse up to $150,000 of Leerink’s legal fees.
The company is not required to sell any shares and there is no minimum offering amount. The program will end when all placement shares are sold or the agreement is terminated. Centessa expects to use any net proceeds for working capital, capital expenditures and general corporate purposes.
Centessa Pharmaceuticals plc is registering an at-the-market offering of American Depositary Shares with an aggregate offering price of up to $250,000,000. The ADSs, each representing one ordinary share, will be sold from time to time through Leerink Partners LLC as sales agent on The Nasdaq Global Select Market under the symbol CNTA, with Leerink earning up to 3.0% of gross proceeds as commission. This is a primary offering, so Centessa will receive the net proceeds, which it plans to use, together with existing cash and investments, to fund development of its product candidates and for general corporate purposes. As context, Centessa had 134,421,149 ordinary shares outstanding as of September 30, 2025, and recently completed a separate underwritten offering that increased pro forma net tangible book value before giving effect to this ATM program.
Centessa Pharmaceuticals plc (CNTA) reported an insider transaction by its General Counsel on a Form 4. On 11/17/2025, the officer exercised a share option to buy 6,000 Ordinary Shares at $5.84 per share and, on the same day, sold 6,000 Ordinary Shares at a weighted average price of $27.6392 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024. Following these transactions, the officer directly owns 105,386 Ordinary Shares and holds 221,559 share options beneficially. Each Ordinary Share may be represented by an American Depositary Share on the market.
Centessa Pharmaceuticals plc (CNTA) reported an insider equity transaction by its Chief Technology & Quality Officer. On 11/17/2025, the officer exercised a share option covering 40,000 Ordinary Shares at an exercise price of $9.42 per share and, on the same date, sold 40,000 Ordinary Shares at a price of $28 per share under a Rule 10b5-1 trading plan adopted on September 14, 2024. After these transactions, the officer directly owned 121,503 Ordinary Shares and held 360,338 derivative securities (share options) beneficially.
Centessa Pharmaceuticals (CNTA) entered an underwriting agreement to sell 11,627,907 American Depositary Shares (ADS) at $21.50 per ADS, with a 30‑day option for underwriters to purchase up to 1,744,186 additional ADS. The offering is being made under an automatic shelf registration on Form S‑3 and is expected to close on November 14, 2025, subject to customary conditions.
The company estimates net proceeds of approximately $234.4 million (or $269.6 million if the option is exercised in full). Centessa plans to use the proceeds, together with existing cash, cash equivalents, and short‑term investments, to fund continued development of its product candidates and for general corporate purposes. With the assumed net proceeds from the firm ADSs, management expects its cash resources to fund operations into 2028.
Centessa Pharmaceuticals plc launched a primary offering of 11,627,907 ADSs at $21.50 per ADS, for gross proceeds of $250,000,000. Underwriting discounts total $15,000,000 ($1.29/ADS), delivering proceeds before expenses of $235,000,000; estimated net proceeds are approximately $234.4 million.
The underwriters have a 30‑day option to purchase up to 1,744,186 additional ADSs. The company plans to use proceeds, together with existing cash, cash equivalents and investments, to fund continued development of product candidates and for general corporate purposes. Delivery is expected on or about November 14, 2025 (T+2).
Shares outstanding were 134,421,149 ordinary shares as of September 30, 2025. The offering results in immediate dilution of $17.84 per ADS to new investors, with an as‑adjusted net tangible book value of $3.66 per ADS after the offering. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and following this offering the company expects funding into 2028. Company, executives and directors agreed to a 60‑day lock‑up; certain shareholders up to 10 trading days.
Centessa Pharmaceuticals (CNTA) launched a preliminary prospectus supplement for a primary offering of American Depositary Shares (ADSs) under its automatic shelf. The underwriters have a 30‑day option to purchase additional ADSs. ADSs trade on Nasdaq Global Select Market; the last reported sale price was $22.33 per ADS on November 10, 2025. Settlement is expected on a T+2 basis.
Centessa expects to use net proceeds, together with existing cash, for continued development of its product candidates and general corporate purposes. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and the company expects funding runway into 2028. Ordinary shares outstanding were 134,421,149 as of September 30, 2025.
Recent R&D updates include ORX750 Phase 2a data across narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with 55 participants completing dosing; ORX750 was generally well tolerated. In IH (2.0 mg, n=17), ORX750 improved mean sleep latency on the MWT (p=0.0213). ORX142 Phase 1 (89 volunteers) showed rapid onset, differentiated PK, and improvements on MWT, with patient studies planned.
The company, its executive officers and directors are subject to lock-up agreements (60 days), with certain shareholders subject to up to 10 trading days, subject to stated exceptions.
Centessa Pharmaceuticals (CNTA) reported Q3 2025 results. The company recorded a net loss of
Operating expenses reflect continued pipeline investment: Q3 research and development was
The SerpinPC program discontinuation charges recognized in 2024 were largely settled by Q3 2025, with the related contract termination liability effectively extinguished.
Centessa Pharmaceuticals (CNTA) furnished an update on its business, announcing financial results for the quarter ended September 30, 2025. The company attached a press release as Exhibit 99.1 and a corporate presentation as Exhibit 99.2, also posted on its investor website.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.
Centessa Pharmaceuticals (CNTA) reported an insider equity update. The company’s Officer (President, Orexin Program) filed a Form 4 showing a tax withholding transaction tied to vested restricted share units. On 11/01/2025, 593 Ordinary Shares were withheld under code F at $24.9 per share to satisfy taxes. Following this administrative withholding, the insider’s beneficial ownership is 193,801 Ordinary Shares, held directly. The filing notes each American Depositary Share currently represents one Ordinary Share.
FAQ
What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?
What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?
